Terbinafine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Terbinafine" in English language version.

refsWebsite

Global rank English rank

13web.archive.org

1^st place

9nih.gov

4^th place

6doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2clincalc.com

3,912^th place

2,496^th place

1drugs.com

399^th place

333^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1handle.net

102^nd place

76^th place

1drugbank.ca

4,294^th place

6,357^th place

1books.google.com

3^rd place

1jfponline.com

low place

1mmm-online.com

low place

1cardiff.ac.uk

low place

7,039^th place

1reuters.com

49^th place

47^th place

1drugsupdate.com

low place

1com.bd

low place

1mercurydrug.com

low place

1pbs.gov.au

low place

1tga.gov.au

3,984^th place

2,622^nd place

books.google.com

Ravina E (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 90. ISBN 978-3-527-32669-3. Archived from the original on 20 December 2016.

cardiff.ac.uk

orca.cardiff.ac.uk

Gupta AK, Stec N, Bamimore MA, Foley KA, Shear NH, Piguet V (March 2020). "The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis" (PDF). Journal of the European Academy of Dermatology and Venereology. 34 (3): 580–588. doi:10.1111/jdv.16101. PMID 31746067. S2CID 208185915.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Terbinafine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

com.bd

medex.com.bd

"Lamisil". Medex.com.bd. Archived from the original on 19 January 2019. Retrieved 17 January 2019.

doi.org

Yan J, Wang X, Chen S (August 2014). "Systematic review of severe acute liver injury caused by terbinafine". International Journal of Clinical Pharmacy. 36 (4): 679–683. doi:10.1007/s11096-014-9969-y. PMID 24986266. S2CID 12867807.
Callen JP, Hughes AP, Kulp-Shorten C (September 2001). "Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases". Archives of Dermatology. 137 (9): 1196–1198. doi:10.1001/archderm.137.9.1196. PMID 11559217.
Duxbury AJ, Oliver RJ, Pemberton MN (March 2000). "Persistent impairment of taste associated with terbinafine". British Dental Journal. 188 (6): 295–296. doi:10.1038/sj.bdj.4800461. PMID 10800234. Persistent loss of taste associated with terbinafine would however appear to be extremely rare.
Trachtman JN, Pagano V (December 2015). "Antifolates and MTHFR". Therapeutic Drug Monitoring. 37 (6): 697–698. doi:10.1097/FTD.0000000000000215. PMID 25929315. S2CID 205604356.
Gupta AK, Stec N, Bamimore MA, Foley KA, Shear NH, Piguet V (March 2020). "The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis" (PDF). Journal of the European Academy of Dermatology and Venereology. 34 (3): 580–588. doi:10.1111/jdv.16101. PMID 31746067. S2CID 208185915.
Mikailov A, Cohen J, Joyce C, Mostaghimi A (March 2016). "Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis". JAMA Dermatology. 152 (3): 276–281. doi:10.1001/jamadermatol.2015.4190. PMID 26716567.

drugbank.ca

"Terbinafine". www.drugbank.ca. Retrieved 14 November 2017.

drugs.com

"Terbinafine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.

drugsupdate.com

"Terbinafine brands in India". Brand index. DrugsUpdate India. Archived from the original on 23 September 2015.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

jfponline.com

Markova T (January 2002). "Clinical inquiries. What is the most effective treatment for tinea pedis (athlete's foot)?". The Journal of Family Practice. 51 (1). Frontline Medical Communications: 21. PMID 11927056. Archived from the original on 6 April 2012.

medicines.org.uk

"Lamisil 1% w/w Cream – Summary of Product Characteristics (SPC) – (eMC)". electronic Medicines Compendium (eMC). 17 March 2016. Archived from the original on 20 December 2016. Retrieved 17 December 2016.

mercurydrug.com

"Mercury Drug – The Leading Drugstore in the Philippines". www.mercurydrug.com. Archived from the original on 18 November 2016. Retrieved 18 November 2016.

mmm-online.com

McGuire S (5 February 2008). "Australian regulators issue warning on Novartis' Lamisil". Medical Marketing and Media. Mmm-online.com. Archived from the original on 9 November 2013. Retrieved 9 November 2013.

nih.gov

pubmed.ncbi.nlm.nih.gov

Crawford F (July 2009). "Athlete's foot". BMJ Clinical Evidence. 2009. PMC 2907807. PMID 21696646.
Yan J, Wang X, Chen S (August 2014). "Systematic review of severe acute liver injury caused by terbinafine". International Journal of Clinical Pharmacy. 36 (4): 679–683. doi:10.1007/s11096-014-9969-y. PMID 24986266. S2CID 12867807.
Markova T (January 2002). "Clinical inquiries. What is the most effective treatment for tinea pedis (athlete's foot)?". The Journal of Family Practice. 51 (1). Frontline Medical Communications: 21. PMID 11927056. Archived from the original on 6 April 2012.
Callen JP, Hughes AP, Kulp-Shorten C (September 2001). "Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases". Archives of Dermatology. 137 (9): 1196–1198. doi:10.1001/archderm.137.9.1196. PMID 11559217.
Duxbury AJ, Oliver RJ, Pemberton MN (March 2000). "Persistent impairment of taste associated with terbinafine". British Dental Journal. 188 (6): 295–296. doi:10.1038/sj.bdj.4800461. PMID 10800234. Persistent loss of taste associated with terbinafine would however appear to be extremely rare.
Trachtman JN, Pagano V (December 2015). "Antifolates and MTHFR". Therapeutic Drug Monitoring. 37 (6): 697–698. doi:10.1097/FTD.0000000000000215. PMID 25929315. S2CID 205604356.
Gupta AK, Stec N, Bamimore MA, Foley KA, Shear NH, Piguet V (March 2020). "The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis" (PDF). Journal of the European Academy of Dermatology and Venereology. 34 (3): 580–588. doi:10.1111/jdv.16101. PMID 31746067. S2CID 208185915.
Mikailov A, Cohen J, Joyce C, Mostaghimi A (March 2016). "Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis". JAMA Dermatology. 152 (3): 276–281. doi:10.1001/jamadermatol.2015.4190. PMID 26716567.

ncbi.nlm.nih.gov

Crawford F (July 2009). "Athlete's foot". BMJ Clinical Evidence. 2009. PMC 2907807. PMID 21696646.

pbs.gov.au

"Terbinafine". Pharmaceutical Benefits Scheme: A-Z list. Australian Government. Archived from the original on 12 February 2014.

reuters.com

"US FDA approves oral granules for scalp ringworm". Reuters. 28 September 2007. Archived from the original on 23 March 2009.

semanticscholar.org

api.semanticscholar.org

Yan J, Wang X, Chen S (August 2014). "Systematic review of severe acute liver injury caused by terbinafine". International Journal of Clinical Pharmacy. 36 (4): 679–683. doi:10.1007/s11096-014-9969-y. PMID 24986266. S2CID 12867807.
Trachtman JN, Pagano V (December 2015). "Antifolates and MTHFR". Therapeutic Drug Monitoring. 37 (6): 697–698. doi:10.1097/FTD.0000000000000215. PMID 25929315. S2CID 205604356.
Gupta AK, Stec N, Bamimore MA, Foley KA, Shear NH, Piguet V (March 2020). "The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis" (PDF). Journal of the European Academy of Dermatology and Venereology. 34 (3): 580–588. doi:10.1111/jdv.16101. PMID 31746067. S2CID 208185915.

tga.gov.au

ebs.tga.gov.au

"PI and CMI Trade Names and Active Ingredients containing Terbinafine". Therapeutic Goods Administration. Australian Government. Archived from the original on 10 September 2017.

web.archive.org

"Terbinafine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
"Lamisil 1% w/w Cream – Summary of Product Characteristics (SPC) – (eMC)". electronic Medicines Compendium (eMC). 17 March 2016. Archived from the original on 20 December 2016. Retrieved 17 December 2016.
Ravina E (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 90. ISBN 978-3-527-32669-3. Archived from the original on 20 December 2016.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
Markova T (January 2002). "Clinical inquiries. What is the most effective treatment for tinea pedis (athlete's foot)?". The Journal of Family Practice. 51 (1). Frontline Medical Communications: 21. PMID 11927056. Archived from the original on 6 April 2012.
"Lamisil (terbinafine): Side Effects". Doublecheckmd.com. 16 June 2010. Archived from the original on 21 September 2013. Retrieved 9 November 2013.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
McGuire S (5 February 2008). "Australian regulators issue warning on Novartis' Lamisil". Medical Marketing and Media. Mmm-online.com. Archived from the original on 9 November 2013. Retrieved 9 November 2013.
"US FDA approves oral granules for scalp ringworm". Reuters. 28 September 2007. Archived from the original on 23 March 2009.
"Terbinafine brands in India". Brand index. DrugsUpdate India. Archived from the original on 23 September 2015.
"Lamisil". Medex.com.bd. Archived from the original on 19 January 2019. Retrieved 17 January 2019.
"Mercury Drug – The Leading Drugstore in the Philippines". www.mercurydrug.com. Archived from the original on 18 November 2016. Retrieved 18 November 2016.
"Terbinafine". Pharmaceutical Benefits Scheme: A-Z list. Australian Government. Archived from the original on 12 February 2014.
"PI and CMI Trade Names and Active Ingredients containing Terbinafine". Therapeutic Goods Administration. Australian Government. Archived from the original on 10 September 2017.